JP2017533912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533912A5 JP2017533912A5 JP2017523273A JP2017523273A JP2017533912A5 JP 2017533912 A5 JP2017533912 A5 JP 2017533912A5 JP 2017523273 A JP2017523273 A JP 2017523273A JP 2017523273 A JP2017523273 A JP 2017523273A JP 2017533912 A5 JP2017533912 A5 JP 2017533912A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cancer
- administered
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 35
- 229960003301 nivolumab Drugs 0.000 claims 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 12
- 201000002528 pancreatic cancer Diseases 0.000 claims 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 12
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 11
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 9
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 9
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 206010014733 Endometrial cancer Diseases 0.000 claims 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 6
- 206010018338 Glioma Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 208000029824 high grade glioma Diseases 0.000 claims 6
- 201000011614 malignant glioma Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 5
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 3
- 238000012447 xenograft mouse model Methods 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 238000009175 antibody therapy Methods 0.000 claims 2
- 102000052833 human CSF1R Human genes 0.000 claims 2
- 102000048362 human PDCD1 Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072035P | 2014-10-29 | 2014-10-29 | |
| US62/072,035 | 2014-10-29 | ||
| US201562157368P | 2015-05-05 | 2015-05-05 | |
| US62/157,368 | 2015-05-05 | ||
| US201562192025P | 2015-07-13 | 2015-07-13 | |
| US62/192,025 | 2015-07-13 | ||
| PCT/US2015/057781 WO2016069727A1 (en) | 2014-10-29 | 2015-10-28 | Combination therapy for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121946A Division JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533912A JP2017533912A (ja) | 2017-11-16 |
| JP2017533912A5 true JP2017533912A5 (enExample) | 2018-12-06 |
| JP6920989B2 JP6920989B2 (ja) | 2021-08-18 |
Family
ID=54695820
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523273A Active JP6920989B2 (ja) | 2014-10-29 | 2015-10-28 | がんのための併用療法 |
| JP2020121946A Pending JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
| JP2022207154A Pending JP2023052067A (ja) | 2014-10-29 | 2022-12-23 | がんのための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121946A Pending JP2020186243A (ja) | 2014-10-29 | 2020-07-16 | がんのための併用療法 |
| JP2022207154A Pending JP2023052067A (ja) | 2014-10-29 | 2022-12-23 | がんのための併用療法 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US9765147B2 (enExample) |
| EP (2) | EP3212670B1 (enExample) |
| JP (3) | JP6920989B2 (enExample) |
| KR (1) | KR102636539B1 (enExample) |
| CN (1) | CN107567336B (enExample) |
| AU (1) | AU2015339306B2 (enExample) |
| BR (1) | BR112017008914A2 (enExample) |
| CA (1) | CA2963147A1 (enExample) |
| CY (1) | CY1123957T1 (enExample) |
| DK (1) | DK3212670T3 (enExample) |
| EA (1) | EA036261B1 (enExample) |
| ES (1) | ES2851390T3 (enExample) |
| HR (1) | HRP20210440T1 (enExample) |
| HU (1) | HUE054012T2 (enExample) |
| IL (1) | IL251464B2 (enExample) |
| LT (1) | LT3212670T (enExample) |
| MX (1) | MX381046B (enExample) |
| PL (1) | PL3212670T3 (enExample) |
| PT (1) | PT3212670T (enExample) |
| RS (1) | RS61602B1 (enExample) |
| SG (1) | SG11201702723VA (enExample) |
| SI (1) | SI3212670T1 (enExample) |
| SM (1) | SMT202100164T1 (enExample) |
| TW (1) | TWI711463B (enExample) |
| WO (1) | WO2016069727A1 (enExample) |
| ZA (1) | ZA201702382B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130302322A1 (en) * | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| KR102418979B1 (ko) * | 2012-05-15 | 2022-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| DK3102605T3 (en) | 2014-02-04 | 2019-02-25 | Pfizer | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATMENT OF CANCER |
| EP3116909B1 (en) | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| MX391735B (es) * | 2014-06-23 | 2025-03-21 | Five Prime Therapeutics Inc | Anticuerpos que se enlazan al receptor del factor 1 estimulador de colonias (csf1r) y sus usos en el tratamiento de trastornos por cd16+ |
| AU2015314756A1 (en) | 2014-09-13 | 2017-03-16 | Novartis Ag | Combination therapies of alk inhibitors |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| WO2016089873A1 (en) * | 2014-12-02 | 2016-06-09 | Celgene Corporation | Combination therapies |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| RS61531B1 (sr) | 2015-04-13 | 2021-04-29 | Five Prime Therapeutics Inc | Kombinovana terapija za kancer |
| WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| CN107660152B (zh) * | 2015-05-27 | 2021-11-05 | Ucb生物制药私人有限公司 | 用于治疗神经系统疾病的方法 |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CR20180318A (es) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
| EP4386005A3 (en) | 2016-06-03 | 2024-09-04 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
| MY189412A (en) | 2016-08-05 | 2022-02-10 | Y Biologics Inc | Antibody to programmed cell death 1 (pd-1) and use thereof |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| WO2018058125A1 (en) | 2016-09-26 | 2018-03-29 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems |
| IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| CA3040914A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| WO2018115051A1 (en) * | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| KR102144658B1 (ko) * | 2017-03-29 | 2020-08-14 | 시오노기세이야쿠가부시키가이샤 | 암 치료용 의약 조성물 |
| US12134654B2 (en) | 2017-04-19 | 2024-11-05 | Marengo Therapeutics, Inc. | Multispecific molecules and uses thereof |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| MX2020002301A (es) | 2017-09-13 | 2020-07-13 | Five Prime Therapeutics Inc | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. |
| WO2019099838A1 (en) * | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| KR102461238B1 (ko) * | 2017-12-05 | 2022-11-01 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료 |
| EP3720881A1 (en) * | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2019139583A1 (en) * | 2018-01-10 | 2019-07-18 | Lee Patrice A | Methods and combination therapy to treat cancer |
| JP7463281B2 (ja) * | 2018-03-05 | 2024-04-08 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法 |
| CN108610422B (zh) * | 2018-03-29 | 2019-05-28 | 中国人民解放军军事科学院军事医学研究院 | 抑制pd-1/pd-l1信号通路的结合分子 |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| JP7407452B2 (ja) * | 2018-07-31 | 2024-01-04 | 国立大学法人北海道大学 | がんの治療及び／又は予防のための医薬 |
| US20220073638A1 (en) * | 2018-09-19 | 2022-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| BR112021022135A2 (pt) | 2019-05-06 | 2023-02-28 | Univ Brown | Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor |
| AU2020282791A1 (en) * | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
| US12098214B2 (en) | 2021-05-13 | 2024-09-24 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2025129066A1 (en) * | 2023-12-15 | 2025-06-19 | The Regents Of The University Of California | Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0382781B1 (en) | 1987-10-23 | 1993-09-29 | Genetics Institute, Inc. | Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2137793C (en) | 1992-06-09 | 2003-04-22 | Jayvardhan Pandit | Crystallization of m-csf |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| AU1804499A (en) | 1997-12-05 | 1999-06-28 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| WO2000025803A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparations |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| PT1223980E (pt) | 1999-10-28 | 2003-10-31 | Reinhold Hofbauer | Utilizacao de inibidores de csf-1 |
| AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| DK1572106T3 (da) | 2002-11-15 | 2010-08-23 | Novartis Vaccines & Diagnostic | Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| AU2004249675B2 (en) | 2003-05-22 | 2010-04-15 | Abbvie Bahamas Ltd. | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| DK2330201T3 (en) | 2003-10-22 | 2017-07-24 | Keck Graduate Inst | PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| WO2005070447A2 (en) | 2004-01-21 | 2005-08-04 | Chiron Corporation | M-csf muteins and uses thereof |
| JP2008506366A (ja) | 2004-05-14 | 2008-03-06 | レセプター バイオロジックス インコーポレイテッド | 細胞表面受容体アイソフォームならびにその同定および使用方法 |
| AU2005267062C1 (en) | 2004-07-22 | 2013-01-17 | Five Prime Therapeutics, Inc. | Compositions and methods of use for MGD-CSF in disease treatment |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| ATE454455T1 (de) | 2005-01-27 | 2010-01-15 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| CA2970873C (en) * | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| WO2007064437A2 (en) | 2005-11-10 | 2007-06-07 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
| EP1977238B1 (en) | 2005-12-22 | 2016-09-28 | Novartis AG | Soluble human m-csf receptor and uses thereof |
| AU2007205048B2 (en) | 2006-01-05 | 2013-07-04 | Novartis Ag | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| US20100266528A1 (en) | 2006-11-17 | 2010-10-21 | Biogen Idec Ma Inc. | Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders |
| WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| US20100298217A1 (en) | 2007-05-30 | 2010-11-25 | Evan Richard Stanley | Csf-1r mutants |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| PT2188313T (pt) | 2007-08-21 | 2017-12-12 | Amgen Inc | Proteínas de ligação ao antigénio c-fms humano |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| US20090148883A1 (en) | 2007-10-31 | 2009-06-11 | Manthey Carl L | Biomarker for assessing response to fms treatment |
| WO2009075344A1 (ja) | 2007-12-12 | 2009-06-18 | Japan As Represented By Director General Of Agency Of National Cancer Center | M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| EP2262836B1 (en) | 2008-03-14 | 2016-03-09 | Transgene SA | Antibody against the csf-1 r |
| JP2011519868A (ja) * | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
| WO2010001617A1 (en) * | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| SI2510010T1 (sl) | 2009-12-10 | 2016-02-29 | F. Hoffmann-La Roche Ag | Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba |
| JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) * | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| WO2012062218A1 (en) * | 2010-11-11 | 2012-05-18 | The University Of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| WO2012082573A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| EP2768861A1 (en) | 2011-10-21 | 2014-08-27 | Institut National de la Sante et de la Recherche Medicale (INSERM) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| KR102418979B1 (ko) | 2012-05-15 | 2022-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| MX2019003934A (es) | 2016-10-06 | 2019-07-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| MX2020000604A (es) | 2017-07-21 | 2020-09-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
-
2015
- 2015-10-28 WO PCT/US2015/057781 patent/WO2016069727A1/en not_active Ceased
- 2015-10-28 HR HRP20210440TT patent/HRP20210440T1/hr unknown
- 2015-10-28 KR KR1020177014031A patent/KR102636539B1/ko active Active
- 2015-10-28 SM SM20210164T patent/SMT202100164T1/it unknown
- 2015-10-28 EP EP15798264.6A patent/EP3212670B1/en active Active
- 2015-10-28 US US14/925,534 patent/US9765147B2/en active Active
- 2015-10-28 MX MX2017005553A patent/MX381046B/es unknown
- 2015-10-28 RS RS20210347A patent/RS61602B1/sr unknown
- 2015-10-28 PL PL15798264T patent/PL3212670T3/pl unknown
- 2015-10-28 CA CA2963147A patent/CA2963147A1/en active Pending
- 2015-10-28 AU AU2015339306A patent/AU2015339306B2/en not_active Ceased
- 2015-10-28 LT LTEP15798264.6T patent/LT3212670T/lt unknown
- 2015-10-28 SG SG11201702723VA patent/SG11201702723VA/en unknown
- 2015-10-28 IL IL251464A patent/IL251464B2/en unknown
- 2015-10-28 HU HUE15798264A patent/HUE054012T2/hu unknown
- 2015-10-28 JP JP2017523273A patent/JP6920989B2/ja active Active
- 2015-10-28 SI SI201531496T patent/SI3212670T1/sl unknown
- 2015-10-28 PT PT157982646T patent/PT3212670T/pt unknown
- 2015-10-28 ES ES15798264T patent/ES2851390T3/es active Active
- 2015-10-28 EP EP20207287.2A patent/EP3835323A1/en not_active Withdrawn
- 2015-10-28 CN CN201580071491.1A patent/CN107567336B/zh active Active
- 2015-10-28 BR BR112017008914A patent/BR112017008914A2/pt not_active Application Discontinuation
- 2015-10-28 TW TW104135474A patent/TWI711463B/zh not_active IP Right Cessation
- 2015-10-28 DK DK15798264.6T patent/DK3212670T3/da active
- 2015-10-28 EA EA201790926A patent/EA036261B1/ru not_active IP Right Cessation
-
2017
- 2017-04-04 ZA ZA2017/02382A patent/ZA201702382B/en unknown
- 2017-08-18 US US15/680,664 patent/US10221244B2/en active Active
-
2019
- 2019-01-09 US US16/243,510 patent/US10618967B2/en active Active
-
2020
- 2020-03-04 US US16/808,910 patent/US11566076B2/en active Active
- 2020-07-16 JP JP2020121946A patent/JP2020186243A/ja active Pending
-
2021
- 2021-03-17 CY CY20211100224T patent/CY1123957T1/el unknown
-
2022
- 2022-12-21 US US18/069,511 patent/US20230212299A1/en not_active Abandoned
- 2022-12-23 JP JP2022207154A patent/JP2023052067A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533912A5 (enExample) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| JP2018070648A5 (enExample) | ||
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| JP2018508512A5 (enExample) | ||
| CN110536905B (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| JP2019519499A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| JP2020508317A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017501167A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2016520082A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2017536408A5 (enExample) | ||
| RU2019133787A (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования | |
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |